Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

NCT05072080 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.

Conditions Studied

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL CHIKV VLP/adjuvant

Study Locations (20)

Florida

  • Jacksonville Center for Clinical Research — Jacksonville
  • Accel Research Sites-DeLand Clinical Research Unit — Lake Mary
  • Optimal Research, LLC — Melbourne
  • Suncoast Research Associates, LLC — Miami
  • Synexus Clinical Research US, Inc. — Pinellas Park
  • Palm Beach Research Center — West Palm Beach

Kansas

  • Johnson County ClinTrials — Lenexa
  • Alliance for Multispecialty Research, LLC — Newton
  • Alliance for Multispecialty Research - Wichita East — Wichita

Alabama

  • Optimal Research, LLC — Huntsville
  • Alliance for Multispecialty Research - Mobile — Mobile

California

  • Velocity Clinical Research, Banning — Banning
  • Optimal Research, LLC — San Diego

Illinois

  • Synexus Clinical Research US, Inc. — Chicago
  • Optimal Research LLC — Peoria

Arizona

  • Alliance for Multispecialty Research, LLC — Tempe

Colorado

  • Lynn Institute of the Rockies — Colorado Springs

Georgia

  • Emory University School of Medicine — Atlanta

Trial Details

FieldValue
Enrollment Target 3,258 participants
Start Date 2021-09-29
Est. Completion 2023-04-03
Phase Phase 3

Sponsor

Bavarian Nordic

16 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05072080

The ClinicalTrials.gov registry entry for NCT05072080 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 3,258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 16 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Chikungunya Virus appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05072080 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Florida, Kansas, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05072080 about?

NCT05072080 is a clinical study titled "A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)". The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.

What is the current status of trial NCT05072080?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,258 participants. The study started on 2021-09-29. Estimated completion is 2023-04-03.

What conditions does trial NCT05072080 study?

This clinical trial studies the following conditions: Chikungunya Virus. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05072080?

The interventions under investigation include: Placebo (BIOLOGICAL), CHIKV VLP/adjuvant (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05072080?

This trial is sponsored by Bavarian Nordic, which has 16 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05072080 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial